Clinical Summary of U.S. Preventive Services Task Force Recommendation
This document is a summary of the 2008 recommendation of the U.S. Preventive Services Task Force (USPSTF) on screening for prostate cancer. This summary is intended for use by primary care clinicians.
Select for copyright and source information.
| Population |
Men Younger than Age 75 Years | Men Age 75 Years or Older |
| Recommendation |
No recommendation
Grade: I (Insufficient Evidence)
| Do not screen
Grade: D
|
| Risk Assessment |
Prostate cancer is more common in older men, African Americans, and men with a family history of prostate cancer.
The same uncertainties about the effects of screening that apply to other men also apply to these higher-risk men.
|
| Screening Tests |
The prostate-specific antigen (PSA) test is more sensitive than the digital rectal examination (DRE).
The conventional PSA test cut-point of 4.0 g/L misses some early cancer. However, lowering the cut-point would increase
the rate of false-positive results. Variations of PSA screening have not yet been demonstrated to improve health outcomes.
|
| Screening Intervals |
If PSA screening reduces mortality, screening every 4 years may be as beneficial as annual screening.
|
| Interventions |
Management strategies for localized prostate cancer include watchful waiting, active surveillance, surgery, and radiation therapy.
There is no consensus regarding optimal treatment.
|
| Balance of harms
and benefits |
- The harms of screening include the discomfort of prostate biopsy and the psychological harm of false-positive test results.
- Harms of treatment include erectile dysfunction, urinary incontinence, bowel dysfunction, and death. A proportion of those treated, and possibly harmed, would never have developed cancer symptoms during their lifetime.
|
For men younger than age 75 years, evidence is inadequate to
determine whether screening improves health outcomes.
Therefore, the balance of harms and benefits
cannot be determined.
| For men age 75 years or older and for those whose life
expectancy is 10 years or fewer, the incremental benefit from
treatment of prostate cancer detected by screening is small to
none.
Therefore, harms outweigh benefits.
|
| Suggestions for practice |
Clinicians should discuss the potential benefits and known harms of PSA screening with their patients younger than age 75 years.
Men in this age group should be informed of the gaps in the evidence, and their personal preferences should
guide the decision of whether to order the test.
|
| Other Relevant USPSTF Recommendations |
A list of USPSTF recommendations on cancer screening can be found at www.preventiveservices.ahrq.gov.
|
For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement (including a summary
of research gaps), and supporting documents, please go to http://www.preventiveservices.ahrq.gov.
Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Return to Contents
Copyright and Source Information
This document is in the public domain within the United States. For
information on reprinting, contact Randie Siegel, Associate Director, Office of Communications and Knowledge Transfer, Agency for Healthcare Research and Quality,
540 Gaither Road, Rockville, MD 20850.
Requests for linking or to incorporate content in electronic resources
should be sent to: info@ahrq.gov.
AHRQ Publication No. 08-05121-EF-3
Current as of August 2008
Internet Citation:
U.S. Preventive Services Task Force. Screening for Prostate Cancer: Clinical Summary of U.S. Preventive Services Task Force Recommendation. AHRQ Publication No. 08-05121-EF-3, August 2008. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/uspstf08/prostate/prostatesum.htm
540 Gaither Road Rockville, MD 20850